All In Biotech

Drug Trial Radar · NCT04241315

ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting

A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Last checked: Nov 19, 2026Latest source record: Mar 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

112

Actual

Start

Mar 26, 2020

Primary completion

Oct 7, 2021

Study completion Nov 1, 2021

Sponsor

Lead sponsor
On Target Laboratories, LLCIndustry
Sponsor type
Industry
Collaborators
Clinipace Worldwide
First posted
Jan 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.

Conditions

  • Lung Neoplasms
  • Lung Cancer

Interventions

  • OTL38 for InjectionDrug

    Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL

  • Near infrared camera imaging systemDevice

    Near infrared camera imaging system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinically Significant Events (CSE)Time frame: 1 day
  2. Localization of Primary NoduleTime frame: 1 day
  3. Identification of Cancerous Synchronous LesionsTime frame: 1 day
  4. Positive Resection MarginsTime frame: 1 day

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Stamford

    Stamford, Connecticut

  • University of Iowa

    Iowa City, Iowa

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Swedish Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.